Joint EBE-EFPIA Position on CE Marking
A Topic Group of the joint Personalised Medicine Working Group has been developing a slide deck highlighting the position of the pharmaceutical industry on the need to consider a risk-based a...
Read moreEBE View on the SPC Manufacturing Waiver
The European Biopharmaceutical Enterprises (EBE) has just released its latest position paper, raising concerns on how the SPC manufacturing waiver will affect innovative biopharmaceutical companies,...
Read moreNew EBE-EFPIA study demonstrates benefits of personalised medicine for patients, society and healthcare systems and makes recommendations for equitable access for patients in Europe
The European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) released today the outcome of the evidence-based analysis on personal...
Read moreEBE announces its 2018-2020 Board of Directors
Brussels, 2 July 2018 – The European Biopharmaceutical Enterprises (EBE), is pleased to announce its Board of Directors for 2018-2020, following the decisions taken at the EBE Annual Meeting on 26 J...
Read moreIncentives, IP and Smaller Companies – the story of uniQure
Download the Case Story in PDF format here uniQure, based in Amsterdam in the Netherlands and Lexington, Massachusetts, USA, is developing curative gene therapies for patients with severe genetic...
Read moreKPMG Report: Site Selection for Life Sciences Companies in Europe 2018
EBE supports the 2018 version of the KPMG report on site selection for life science companies in Europe, developed in collaboration with Venture Valuation. Each company seeking to establish European...
Read moreEBE statement on the European Commission’s proposal to introduce an SPC manufacturing waiver, which puts patient care at risk
Brussels – After the European Commission released its proposal to introduce a Supplementary Protection Certificates (SPCs) manufacturing waiver today, the European Biopharmaceutical Enterprises (EBE...
Read moreIn memory of Eugenio Aringhieri, CEO Dompé, member of the EBE Board of Directors
It is with great sadness that we received the news of the sudden and untimely passing of our Board member Eugenio Aringhieri, CEO Dompé, on 1 May 2018. Eugenio Aringhieri has contributed to th...
Read moreStatement in response to the EU Council ratifying the Brexit transition deal
The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today respond...
Read moreEuropean Investment Bank report: “Financing the next wave of medical breakthroughs – What works and what needs fixing?”
EBE was proud to support the launch of the European Investment Bank's report "Access-to-finance conditions for Life Sciences R&D" at BioEurope Spring. This reports identifies a number of neces...
Read more